REGISTER
Charles M. Rudin on Tarlatamab in SCLC and the Value of Longer Follow-up
At ESMO 2026, Charles M. Rudin discusses extended follow-up from DeLLphi-304 in previously treated small cell lung cancer, the implications of DeLLphi-305 for first-line maintenance, and why early monitoring for cytokine release syndrome and neurotoxicity matters with DLL3-directed T-cell engagers.

0
0
Loading